
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by…












